NEW YORK (GenomeWeb News) — Kinaxo Biotechnologies has received around €1 million (approximately $1.4 million) from the German Ministry for Education and Research to develop a “universally applicable” chemical proteomics tool, the company said Monday.
The company said it plans to use the platform to “quantify small molecule-protein interactions in mammalian tissues and cell lines.”
Kinaxo’s head of research, Klaus Godl, said the company will use the funds to combine mass spectrometry with its KinaTor technology, in order to distinguish relevant drug-protein interactions from weak binding as well as determine a “compound’s affinity without the need of in vitro assays.”
These technologies are to be developed with help from Lothar Jänsch of the Helmholtz Institute and Henrik Daub of the Max Planck Institute.